Literature DB >> 18936635

Spectral domain optical coherence tomography and glaucoma.

Teresa C Chen1, Audrey Zeng, Wei Sun, Mircea Mujat, Johannes F de Boer.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18936635      PMCID： PMC2679587          DOI： 10.1097/IIO.0b013e318187e801

Source DB:  PubMed          Journal:  Int Ophthalmol Clin        ISSN： 0020-8167


× No keyword cloud information.
  50 in total

1.  Discriminating between normal and glaucomatous eyes using the Heidelberg Retina Tomograph, GDx Nerve Fiber Analyzer, and Optical Coherence Tomograph.

Authors:  L M Zangwill; C Bowd; C C Berry; J Williams; E Z Blumenthal; C A Sánchez-Galeana; C Vasile; R N Weinreb
Journal:  Arch Ophthalmol       Date:  2001-07

2.  In vivo human retinal imaging by Fourier domain optical coherence tomography.

Authors:  Maciej Wojtkowski; Rainer Leitgeb; Andrzej Kowalczyk; Tomasz Bajraszewski; Adolf F Fercher
Journal:  J Biomed Opt       Date:  2002-07       Impact factor: 3.170

3.  Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging.

Authors:  Teresa C Chen; Barry Cense; Mark C Pierce; Nader Nassif; B Hyle Park; Seok H Yun; Brian R White; Brett E Bouma; Guillermo J Tearney; Johannes F de Boer
Journal:  Arch Ophthalmol       Date:  2005-12

4.  In vivo dynamic human retinal blood flow imaging using ultra-high-speed spectral domain optical coherence tomography.

Authors:  Brian White; Mark Pierce; Nader Nassif; Barry Cense; B Park; Guillermo Tearney; Brett Bouma; Teresa Chen; Johannes de Boer
Journal:  Opt Express       Date:  2003-12-15       Impact factor: 3.894

5.  Ultrahigh-resolution high-speed retinal imaging using spectral-domain optical coherence tomography.

Authors:  Barry Cense; Nader Nassif; Teresa Chen; Mark Pierce; Seok-Hyun Yun; B Park; Brett Bouma; Guillermo Tearney; Johannes de Boer
Journal:  Opt Express       Date:  2004-05-31       Impact factor: 3.894

6.  Pulsed-source and swept-source spectral-domain optical coherence tomography with reduced motion artifacts.

Authors:  S H Yun; G Tearney; J de Boer; B Bouma
Journal:  Opt Express       Date:  2004-11-15       Impact factor: 3.894

7.  Baseline optical coherence tomography predicts the development of glaucomatous change in glaucoma suspects.

Authors:  Maziar Lalezary; Felipe A Medeiros; Robert N Weinreb; Christopher Bowd; Pamela A Sample; Ivan M Tavares; Ali Tafreshi; Linda M Zangwill
Journal:  Am J Ophthalmol       Date:  2006-10       Impact factor: 5.258

8.  Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons.

Authors:  L A Kerrigan-Baumrind; H A Quigley; M E Pease; D F Kerrigan; R S Mitchell
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-03       Impact factor: 4.799

9.  Histologic correlation of in vivo optical coherence tomography images of the human retina.

Authors:  Teresa C Chen; Barry Cense; Joan W Miller; Peter A D Rubin; Daniel G Deschler; Evangelos S Gragoudas; Johannes F de Boer
Journal:  Am J Ophthalmol       Date:  2006-06       Impact factor: 5.258

10.  Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss.

Authors:  A Sommer; J Katz; H A Quigley; N R Miller; A L Robin; R C Richter; K A Witt
Journal:  Arch Ophthalmol       Date:  1991-01
View more
  20 in total

1.  Choroidal thickness measured by spectral domain optical coherence tomography: factors affecting thickness in glaucoma patients.

Authors:  Eugenio A Maul; David S Friedman; Dolly S Chang; Michael V Boland; Pradeep Y Ramulu; Henry D Jampel; Harry A Quigley
Journal:  Ophthalmology       Date:  2011-04-13       Impact factor: 12.079

2.  Diagnostic capability of spectral-domain optical coherence tomography for glaucoma.

Authors:  Huijuan Wu; Johannes F de Boer; Teresa C Chen
Journal:  Am J Ophthalmol       Date:  2012-01-20       Impact factor: 5.258

Review 3.  Noninvasive methods of detecting increased intracranial pressure.

Authors:  Wen Xu; Patrick Gerety; Tomas Aleman; Jordan Swanson; Jesse Taylor
Journal:  Childs Nerv Syst       Date:  2016-06-28       Impact factor: 1.475

4.  Repeatability of nerve fiber layer thickness measurements in patients with glaucoma and without glaucoma using spectral-domain and time-domain OCT.

Authors:  Marc Töteberg-Harms; Veit Sturm; Pascal B Knecht; Jens Funk; Marcel N Menke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-10       Impact factor: 3.117

5.  Reproducibility of retinal nerve fiber layer thickness measurements using spectral domain optical coherence tomography.

Authors:  Huijuan Wu; Johannes F de Boer; Teresa C Chen
Journal:  J Glaucoma       Date:  2011-10       Impact factor: 2.503

6.  Simultaneous optical coherence tomography and laser induced fluorescence imaging in rat model of ovarian carcinogenesis.

Authors:  Lida P Hariri; Erica R Liebmann; Samuel L Marion; Patricia B Hoyer; John R Davis; Molly A Brewer; Jennifer K Barton
Journal:  Cancer Biol Ther       Date:  2010-09-01       Impact factor: 4.742

7.  Evaluation of optic nerve head and retinal nerve fiber layer in early and advance glaucoma using frequency-domain optical coherence tomography.

Authors:  Songfeng Li; Xiaozhen Wang; Shuning Li; Gewei Wu; Ningli Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-11-25       Impact factor: 3.117

8.  Laparoscopic optical coherence tomography imaging of human ovarian cancer.

Authors:  Lida P Hariri; Garret T Bonnema; Kathy Schmidt; Amy M Winkler; Vrushali Korde; Kenneth D Hatch; John R Davis; Molly A Brewer; Jennifer K Barton
Journal:  Gynecol Oncol       Date:  2009-05-29       Impact factor: 5.482

9.  Intraluminal Deposits Found in Glaucoma Tube Shunts Via Anterior Segment Ocular Coherence Tomography.

Authors:  Jorge A Alvarado; Vinita Srivastava; Yang Sun
Journal:  J Glaucoma       Date:  2018-03       Impact factor: 2.503

10.  Comparative analysis of mean retinal thickness measured using SD-OCT in normal young or old age and glaucomatous eyes.

Authors:  Jun Won Jang; Myung Won Lee; Kyong Jin Cho
Journal:  Int Ophthalmol       Date:  2017-10-12       Impact factor: 2.031
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.